Biological agents such as antitumor necrosis factor (TNF)-a antibodies, vedolizumab (anti-a4b7 integrin antibody) and ustekinumab (interleukin [IL]-12/IL-23 antibody) have also been used to treat severe forms of IBD. Here, TNF is linked to inflammatory bowel disease.